The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish ...

Dr. Chao H. Huang explains his skepticism regarding a recent study that linked chronic pain to significantly higher lung ...

Cells expressing the basal cell marker KRT5 have been fluorescently labelled and can be seen spreading throughout the bronchial tree The ‘cell of origin’ of the second most common lung cancer and the ...

A recent study has uncovered an unexpected connection between our diets and the progression of lung cancer, specifically a ...

A pregnancy-related protein, PZP, shows promise as a biomarker for poor survival and immune changes in women with lung ...

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.’s (NASDAQ:LTRN) ...

Cells expressing the basal cell marker KRT5 have been fluorescently labelled and can be seen spreading throughout the bronchial tree The ‘cell of origin’ of the second most common lung cancer ...

The new screening panel offers gender-specific diagnostics and hereditary risk assessment aimed at improving early cancer ...

Morgan Rynor reports there are genetic mutations that could indicate an elevated risk for colon, lung, rectal, prostate and other cancers. Depending on the marker, there are different routes a patient ...

The analysis showed that blood testing improved early diagnosis for a wide variety of cancers. Compared with standard cancer ...

Cancer care has changed dramatically over the last decade. As opposed to a "one-size-fits-all" approach, treatment today is ...